The interim for CD17 (severe, that sounded like they're expecting it to start today), will require 245 patients (40% enrolled) + 28 days, but the interim for CD16 (critical) will only require 127 patients (40%) + 28 days. Yes, it sounds like they're expecting CD16 to start next week. The real good news is that we now have confirmation that both trials are in the Red zone and getting ready to start. Given the large number of trials sites and that they're already screening patients, I'm expecting they'll have the interim results for critical before they get them for severe, especially given the PE for critical is very straightforward (death or respiratory failure). I also believe this is where all eyes will be focused relative to getting a fast EUA for Brazil and the Philippines, and an eye opener for the FDA.